|
Acth-Independent Macronodular Adrenal Hyperplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Two variants found in AIMAH patients were transiently expressed in HEK 293 and adrenocortical H295R cells for further functional studies.
|
22996146 |
2012 |
|
Acute lymphocytic leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
|
27922598 |
2017 |
|
Acute lymphocytic leukemia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The CNVs of EphA3 were associated with multiple types of hematologic malignancies including ALL, AML, CLL, CML, MM, and MDS.
|
21454190 |
2011 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
RKIP silencing in immortalized HEK-293 cells (termed HEK-499) correlated significantly with KEAP 1 protein degradation and subsequent NRF2 addiction in these cells.
|
22279539 |
2012 |
|
Adenocarcinoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Our data shows that homozygous or heterozygous loss of EphA3 does not alter the progression of murine adenocarcinomas that result from Kras mutation or loss of Trp53, and we detected negligible postnatal expression of EphA3 in adult wild-type lungs.
|
25713296 |
2015 |
|
Adenocarcinoma of large intestine
|
0.010 |
Biomarker
|
disease |
BEFREE |
All the synthesised ligands and their metal complexes were assessed for in vitro cytotoxicity against human colorectal adenocarcinoma (DLD-1), cervix carcinoma (HeLa), breast adenocarcinoma (MDA-MB-231), colon adenocarcinoma (HT-29), endometrial adenocarcinoma (ECC-1), prostate cancer (DU-145 and PC-3), normal embryonic kidney (HEK-293), normal prostate epithelium (PNT-1A), and normal retinal pigment epithelium (ARPE-19) cells.
|
30362387 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.320 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Moreover, EPHA3 gene copy numbers and/or expression levels were decreased in tumors from large cohorts of patients with lung cancer (eg, the gene was deleted in 157 of 371 [42%] primary lung adenocarcinomas).
|
22829656 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We report here a thorough study to address the physiological role of the putative lung cancer tumor suppressor EPH receptor A3 (EPHA3), a gene that is frequently mutated in human lung adenocarcinomas.
|
25713296 |
2015 |
|
Adenocarcinoma of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on these findings, we have synthesized some new diflunisal thiosemicarbazides and 1,2,4-triazoles and tested them against androgen-independent prostate adenocarcinoma (PC-3), colon carcinoma (HCT-116), human breast cancer (T47D), breast carcinoma (MCF7) and human embryonic kidney (HEK-293) cell lines.
|
30082676 |
2018 |
|
Adrenal Gland Pheochromocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SK-N-SH (neuroblastoma) and PC-12 (phaeochromocytoma) cells were used and compared with HEK-293 cells transfected with OCT1, OCT2 and OCT3, respectively.
|
19324274 |
2009 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The CNVs of EphA3 were associated with multiple types of hematologic malignancies including ALL, AML, CLL, CML, MM, and MDS.
|
21454190 |
2011 |
|
Adult Fibrosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cytotoxicity of the compounds was examined in human embryonic kidney (HEK-293), human ovarian cancer (SKOV-3), human fibrosarcoma (HT-1080), and human leukemia (CCRF-CEM) cells.
|
30396106 |
2019 |
|
Adult Glioblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
EphA3 was overexpressed in up to 60% of glioblastoma tumors tested, but not in normal brain.
|
27494882 |
2016 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma.
|
30562956 |
2018 |
|
Adult Glioblastoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The above results indicated that anti-EPHA3-modified NPs may potentially serve as a nose-to-brain drug carrier for the treatment of glioblastoma.
|
30176744 |
2018 |
|
Adult Glioblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the regulation of EphA3 expression plays a critical role in glioblastoma cell growth in non-adherent conditions.
|
30528229 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
EphA3 was not detected in normal peripheral T cells, in any subset of thymus-derived developing T cells, or in Hodgkin's lymphoma.
|
14697337 |
2004 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, cytotoxicity of the AgNPs was investigated against human cervical cancer (HeLa), human liver cancer (HepG2), and human embryonic kidney (HEK-293) cell lines using 5-fluorouracil as a positive control.
|
31330905 |
2019 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified two targets, fibrillin 2 and EphA3, which specifically stain medulloblastoma.
|
22904683 |
2012 |
|
Adult Rhabdomyosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that EphA3 expression may define subsets of RMS tumours, and that EphA3 suppresses motility through regulation of Rho GTPases in RMS cells.
|
18814179 |
2008 |
|
Adult Rhabdomyosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In human rhabdomyosarcoma (RD) and embryonic kidney (HEK-293T) cell lines coinfected at a 1 : 1 ratio, wild-type nsP4-82R virus was rapidly outcompeted by nsP4-82S virus as early as one passage (3 days).
|
31613205 |
2019 |
|
Adult Solid Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
G-11 was able to exert cytotoxic effect on hematological (Jurkat, U937, K562, HL-60, CCRF-SB) and solid tumor (MCF-7, HepG2, HeLa, Caco-2) cell lines, with IC50 values significantly lower than noncancerous cells (HEK-293, BJ and Vero) and normal peripheral blood mononuclear cells.
|
26916980 |
2016 |
|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ<sub>1-42</sub> accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APP<sub>sw</sub>).
|
30397132 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
CNVs in coding regions of the MAP4K3, HLA-B, EPHA3 and DPYD genes were detected however, after validation by Log R Ratio (LRR) values and TaqMan CNV genotyping, only EPHA3 deletion remained as a potential protective factor for ALS (p = 0.0065024).
|
23991104 |
2013 |